Technical Analysis for ZYME - Zymeworks Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 1.18% | |
| Narrow Range Bar | Range Contraction | 1.18% | |
| Up 3 Days in a Row | Strength | 1.18% | |
| Oversold Stochastic | Weakness | 1.18% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.38% | |
| Oversold Stochastic | Weakness | 2.38% | |
| Stochastic Buy Signal | Bullish | 2.50% |
| Alert | Time |
|---|---|
| Down 1% | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| Fell Below 10 DMA | about 7 hours ago |
| Up 1% | about 10 hours ago |
| 10 DMA Support | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Zymeworks Inc. Description
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.14 |
| 52 Week Low | 6.015 |
| Average Volume | 432,804 |
| 200-Day Moving Average | 9.14 |
| 50-Day Moving Average | 8.78 |
| 20-Day Moving Average | 8.73 |
| 10-Day Moving Average | 8.46 |
| Average True Range | 0.33 |
| RSI (14) | 47.09 |
| ADX | 13.66 |
| +DI | 21.11 |
| -DI | 18.44 |
| Chandelier Exit (Long, 3 ATRs) | 8.91 |
| Chandelier Exit (Short, 3 ATRs) | 9.20 |
| Upper Bollinger Bands | 9.47 |
| Lower Bollinger Band | 7.99 |
| Percent B (%b) | 0.42 |
| BandWidth | 17.00 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.11 |
| MACD Histogram | -0.016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.97 | ||||
| Resistance 3 (R3) | 8.94 | 8.80 | 8.91 | ||
| Resistance 2 (R2) | 8.80 | 8.70 | 8.81 | 8.89 | |
| Resistance 1 (R1) | 8.70 | 8.65 | 8.75 | 8.73 | 8.87 |
| Pivot Point | 8.56 | 8.56 | 8.58 | 8.57 | 8.56 |
| Support 1 (S1) | 8.46 | 8.46 | 8.51 | 8.49 | 8.35 |
| Support 2 (S2) | 8.32 | 8.41 | 8.33 | 8.33 | |
| Support 3 (S3) | 8.22 | 8.32 | 8.31 | ||
| Support 4 (S4) | 8.25 |
